{"id":"8f4209f3d6a3","type":"article","url":"https://hartvaat.nl/2026/03/01/journal-club-ivaleptische-nefropathie-bij-complement-gemedieerde-trombotische-mi/","title":"Journal Club: ivaleptische nefropathie bij complement-gemedieerde trombotische microangiopathie","title_en":"journal club","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["complementremmers","iga-nefropathie","immunoadsorptie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01043-9/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01043-9/fulltext","authors":[],"significance":6,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"This Journal Club discussed the clinical implications of the VALIANT trial results from the New England Journal of Medicine, addressing contemporary treatment approaches in nephrology.","created":"2026-07-03T10:25:14Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In deze Journal Club-bespreking wordt de VALIANT-trial besproken (N Engl J Med 2025), met commentaar over de klinische implicaties voor nefrologen.","abstract_original":"Fakhouri et al.; for the VALIANT Trial Investigators. (N Engl J Med. 2025;393:2210–2220.)"}